These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 30612709)

  • 1. Closing in on targeted therapy for acute myeloid leukaemia.
    The Lancet Haematology
    Lancet Haematol; 2019 Jan; 6(1):e1. PubMed ID: 30612709
    [No Abstract]   [Full Text] [Related]  

  • 2. Availability of FLT3 inhibitors: how do we use them?
    Perl AE
    Blood; 2019 Aug; 134(9):741-745. PubMed ID: 31243041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
    Weis TM; Marini BL; Bixby DL; Perissinotti AJ
    Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical use.
    Abdul-Hamil NA; Wong GC; Nagarajan C; Martinelli G; Cherchione C
    Minerva Med; 2020 Oct; 111(5):443-454. PubMed ID: 32955824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FLT3 inhibitors in acute myeloid leukemia: Current and future.
    Thomas CM; Campbell P
    J Oncol Pharm Pract; 2019 Jan; 25(1):163-171. PubMed ID: 30270754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment with gilteritinib for initially FMS-like tyrosine kinase 3 gene internal tandem duplications-positive elderly refractory acute myeloid leukemia that changed into FMS-like tyrosine kinase 3 gene tyrosine kinase domain-positive after cord blood transplantation.
    Akahane D; Moriyama M; Yoshizawa S; Katagiri S; Fujimoto H; Gotoh A
    Geriatr Gerontol Int; 2019 Oct; 19(10):1063-1064. PubMed ID: 31602758
    [No Abstract]   [Full Text] [Related]  

  • 7. RNA-based
    Cucchi DGJ; Denys B; Kaspers GJL; Janssen JJWM; Ossenkoppele GJ; de Haas V; Zwaan CM; van den Heuvel-Eibrink MM; Philippé J; Csikós T; Kwidama Z; de Moerloose B; de Bont ESJM; Lissenberg-Witte BI; Zweegman S; Verwer F; Vandepoele K; Schuurhuis GJ; Sonneveld E; Cloos J
    Blood; 2018 May; 131(22):2485-2489. PubMed ID: 29669779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Midostaurin in FLT3-mutated acute myeloid leukaemia.
    Das M
    Lancet Oncol; 2017 Aug; 18(8):e439. PubMed ID: 28669736
    [No Abstract]   [Full Text] [Related]  

  • 9. First new drug approval for AML in 15 years.
    Sheridan C
    Nat Biotechnol; 2017 Aug; 35(8):696-698. PubMed ID: 28787411
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia.
    Weisberg E; Meng C; Case AE; Tiv HL; Gokhale PC; Buhrlage SJ; Yang J; Liu X; Wang J; Gray N; Adamia S; Sattler M; Stone R; Griffin JD
    J Cell Mol Med; 2020 Mar; 24(5):2968-2980. PubMed ID: 31967735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
    Luskin MR; DeAngelo DJ
    Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Midostaurin for the treatment of acute myeloid leukemia.
    Patnaik MM
    Future Oncol; 2017 Sep; 13(21):1853-1871. PubMed ID: 28610444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
    Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M
    Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance.
    Joshi SK; Sharzehi S; Pittsenbarger J; Bottomly D; Tognon CE; McWeeney SK; Druker BJ; Traer E
    Am J Hematol; 2021 Jul; 96(7):E226-E229. PubMed ID: 33780043
    [No Abstract]   [Full Text] [Related]  

  • 15. Overcoming Resistance to FLT3 Inhibitors in the Treatment of
    Lam SSY; Leung AYH
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets.
    Bruno S; Borsi E; Patuelli A; Bandini L; Mancini M; Forte D; Nanni J; Barone M; Grassi A; Cristiano G; Venturi C; Robustelli V; Atzeni G; Mosca C; De Santis S; Monaldi C; Poletti A; Terragna C; Curti A; Cavo M; Soverini S; Ottaviani E
    Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments.
    Scholl S; Fleischmann M; Schnetzke U; Heidel FH
    Cells; 2020 Nov; 9(11):. PubMed ID: 33212779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FLT3 inhibitors for acute myeloid leukemia.
    Lancet JE
    Clin Adv Hematol Oncol; 2015 Sep; 13(9):573-5. PubMed ID: 26452187
    [No Abstract]   [Full Text] [Related]  

  • 19. Preliminary data on ASP2215: tolerability and efficacy in acute myeloid leukemia patients.
    Thom C
    Future Oncol; 2015 Sep; 11(18):2499-501. PubMed ID: 26279055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
    Garcia JS; Percival ME
    Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.